Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
This conversation centers around two thoughts about the EASL Congress 2024 from Michelle Long.one on network value and the other on the reat benefit that comes from reviewing abstracts in advance.
EASL Secretary General Aleksander Krag offers his vision for the EASL Congress 2024, after which Hannes Hagstrom shared some impressions.
EASL Secretary General Aleksander Krag and our other guests, Hannes Hagstrom and Michelle Long, join Jörn Schattenberg and Roger Green to discuss MASLD-related highlights of EASL Congress 2024.
This week’s vault episode offers the last time Stephen Harrison presented results of a specific drug trial on the podcast.
This second conversation with Dimitar Tonev and Roger Green focus on some of the elements of Stephen’s personality that made him a role model for the entire community in Dimitar’s eyes.
Dimitar Tonev and Roger Green discuss Stephen Harrison’s role as a major innovator in the MASLD space, with Dimitar focusing largely on Stephen developing the first clinical trial site network.
Donna Cryer, Jörn Schatenberg and Roger Green reflect on Stephen Harrison’s ability to bring together all the various elements of the MASLD community in pursuit of knowledge and a first approved drug.
In two separate conversations, Global Liver Institute Founder and CEO and industry executive and consultant hepatologist Dimitar Tonev share memories of Stephen Harrison with co-hosts Jörn Schattenberg and Roger Green.
